Dopamine hypersensitivity in migraine: Role of the apomorphine test

Clinical Neuropharmacology

Volumn 20, Issue 1, 1997, Pages 36-41

  Cerbo, R ^a   Barbanti, P ^a   Buzzi, M G ^b   Fabbrini, G ^b   Brusa, L ^b   Roberti, C ^b   Zanette, E ^b   Lenzi, G L ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Inst Mediterraneo di Neurosci N   (Italy)

Author keywords

Apomorphine; Domperidone; Dopamine receptors; Migraine

Indexed keywords

APOMORPHINE; DOMPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HYPERSENSITIVITY; MALE; MIGRAINE; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031019130     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199702000-00004     Document Type: Article

References (18)

1. Horowski R. Some aspects of the dopaminergic action of ergot derivatives and their role in the treatment of migraine. In: Critchley M, et al., eds Advances in neurology. New York; Raven Press, 1982;33:325-34.
2. Waelkens J. Dopamine in the prevention of complete classical migraine, Br Med J 1984;284:294.
3. Welch KMA. Drug therapy of migraine. N Engl J Med 1993;329:1476-83.
4. Drago F, Continella G, Mangano O, Canonico PL, Beranardini R, Scapagnmi U. Neuroendocrine and behavioral effect of flunarizine in young and old rats. Cephalalgia 1985;5:125-9.
5. Blin O, Azulay JF, Masson G, Aubrespy G, Serratrice G. Apomorphine-induced yawning in migraine patients: enhanced responsivenss. Clin Neuropharmacol 1991;14:91-5.
6. Fanciullacci M, Michelacci S, Curradi C, Sicuteri F. Hyperresponsiveness of migraine patients to the hypotensive aciion of bromocriptine. Headache 1980;2:99-102.
7. Sicuteri F, Fanciullacci M, Michelacci S. Decentralisation supersensitivity in headathe and central panalgesia. Res Clin Stud Headache 1978;6:9-33.
8. Bes A, Geraud G, Guell A, Arné-Bes MC. Hypersensibilité dopaminergique dans la migraine: un test diagnostique? Nouv Presse Med 1982;11:1475-8.
9. Cangi F, Fanciullacci M, Petrini U, et al. Apomorphine as an unmasker for migraine [Abstract]. Presented at the First International Headache Congress. Munich, Sept. 14-16, 1983.
10. Amery WK, Waelkens J, Caers I. Dopaminergic mechanisms in premonitory phenomena. In: Amery WK, Wauquier A, eds. The prelude to the migraine attack. London: Bailliere Tindall, 1986:64-77.
11. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders. cranial neuralgias aiui facial pain, Cephalalgia 1988;8:1-96.
12. Fabre N, Gu XH, Geraud G, Pavy-Le-traon A, Bes A, Middle cerebral arteries flow, velocities in headache-free migraineurs: effects ot apomorphme. Cephalalgia 1991;11-44-5.
13. Sicuteri F, Boccuni M, Cangi F. Dopamine agonists: from unmaskers of functional denervation to prophylactic drug in migraine treatment. Cephalalgia 1991;11:215-6.
14. Gancher ST, Nutt JG, Woodward WR. Absorption of apomorphine by various routes in parkinsonism. Mov Disord 1991;6:212-6.
15. Corsini GU, Del Zompo M, Melis GB, Mangoni A, Gessa GL. (-) Sulpiride as a specific antagonist of "low dose" effects of apomorphine in humans. In: Spano PF, Trabucchi M, Corsini GU, Gessa GL, eds. Sulpiride and other benzamides. Milano: Italian Brain Research Foundation Press, 1979:255-66.
16. Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D' Antonio P, Apomorphine test in de novo Parkinson's disease. Funct Neurol 1992;7:295-8.
17. 5receptors in peripheral blood lymphocytes in migraineurs. In: Clifford Rose F, ed. New advances in headache research. London: Smith Gordon Nishimura, 1994:83-7.
18. Del Zompo M, Lai M, Loi V, Pisano MR. Dopamine hypersensitivity in ap[morphine syncope. Headache 1995;35:222-4.